Takayanagi et al. Molecular differences between hemangioblastomas

NeuroOncology
tissue microdissection analysis verified that the stromal cells are the neoplastic cells harboring the genetic alterations. 3 Among all diagnosed HBs in patients, 75% occur sporadically and 25% occur as a part of von Hippel-Lindau (VHL) disease, 4 an autosomal dominant hereditary disease caused by a germline mutation of the VHL gene that predisposes individuals to multi-organ tumors, including clear cell renal cell carcinoma (ccRCC), pheochromocytomas, pancreatic islet tumors, retinal angiomas, as well as HBs. 5 HBs occur most frequently in the cerebellum, followed by the brainstem and spinal cord, and the spinal HBs are more likely to be observed in patients with VHL disease than in patients with sporadic HBs. 6 Surgical resection is the standard treatment of HBs, while stereotactic radiosurgery is reported to be an effective alternative for small HBs. 7 In 1993, VHL, the tumor suppressor gene that causes VHL disease, was identified and mapped to chromosome (chr.) 3p25 via positional cloning. 8 Then, somatic mutations of VHL were also found in sporadic HBs. 9 The VHL protein is involved in degradation of hypoxia inducible factor (HIF)-1 and HIF-2, which promote transcription of vascular endothelial growth factor and platelet-derived growth factor in hypoxic conditions. 10, 11 When the normal VHL protein function is lost due to VHL mutation or deletion, HIF proteins do not undergo the VHL-mediated degradation and therefore activate transcription of these downstream growth factors that promote tumorigenesis in VHL disease. 11 A previous report on integrated genome analysis of ccRCCs demonstrated that VHL intragenic mutation, deletions of chr. 3 involving VHL, and VHL promoter methylation were present in 82%, 94%, and 10% of sporadic ccRCCs, respectively. 12 The rate of biallelic VHL inactivation in sporadic ccRCC was nearly 98% and indicated that biallelic VHL inactivation is an important mechanism during ccRCC tumorigenesis; this mechanism is consistent with Knudson's 2-hit theory, which explains the importance of biallelic inactivation of tumor suppressor genes in inherited cancer susceptibility syndromes. 13 In contrast, several studies reported that inactivation of VHL is less frequent in HB than in RCC, especially in sporadic HB. 14, 15 These studies reported that the rates of biallelic inactivation of VHL in sporadic HB were 10% to 33%. Even with next-generation sequencing, Shankar et al reported that the rates of VHL mutation and biallelic inactivation of VHL in sporadic HBs were 56% and 46%, respectively. 16 Therefore, it is possible that the biallelic VHL inactivation is not essential in HB tumorigenesis. Alternatively, the lower incidence of biallelic inactivation of VHL and apparent absence of VHL promoter methylation in HB could be due to technological limitations of the analytical approaches used.
To reevaluate the contribution of VHL inactivation to HB tumorigenesis, we used multiple analytical genetic techniques to comparatively analyze VHL-related and sporadic HBs. Our findings suggested that in addition to well-known mechanisms such as mutation or deletion of VHL, epigenetic suppression of VHL as well as other unknown mechanisms may play roles in the pathogenesis of sporadic HB.
Materials and Methods
Patients and Tumor Specimens
Thirty-two surgically resected HB specimens from 28 patients treated at the University of Tokyo Hospital between 1995 and 2012 were analyzed retrospectively. Of the 32 specimens, 11 were VHL-related HBs from 7 patients, and 21 were sporadic HBs from 21 patients. The 7 patients with VHL disease included 2 pairs of siblings; therefore, 5 families were represented by VHL-related HBs. In the cases in which multiple HBs were resected from one patient, each tumor was resected on a separate date. For all tumor specimens, paired peripheral blood samples were also obtained to be used as patient-specific normal genetic controls. Histopathological diagnosis was made according to the 2007 World Health Organization classification. 1 Diagnoses of VHL disease were made according to the clinical criteria. 17 This study was approved by the Ethics Committee of the University of Tokyo (#G3512). All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments. Written informed consent was obtained from all individual participants included in the study.
DNA Extraction
The QIAamp DNA mini kit (Qiagen) was used to extract a genomic DNA sample from each frozen tumor sample and each paired blood sample, according to the manufacturer's instructions.
Direct Sequencing
The 3 exons of VHL were amplified using 6 primer sets described by Weil et al. 18 An aliquot of DNA was amplified
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by PCR using AmpliTaq Gold DNA polymerase (Applied Biosystems) with annealing temperature at 60°C. Direct sequencing was then performed with an ABI Genetic Analyzer 3130xL or an ABI DNA Analyzer 3730xL (Applied Biosystems). According to the method used by Shankar et al, 16 tumor purity (P T /target) was further estimated from the allele frequency of the VHL alterations (AF VHL ) in the 3 following scenarios: (i) if loss of heterozygosity (LOH) of chr. 3 represents a copy neutral event, then the tumor purity (P T /target) is given by the following equation: P T /target = AF VHL ; (ii) if LOH of chr. 3 is a result of haploidization, then the tumor purity is given by: P T /target = 2 × AF VHL /(1 + AF VHL ); (iii) if LOH of chr. 3 was not detected, then the tumor purity is given by: P T /target = 2 × AF VHL .
Single Nucleotide Polymorphism Arrays
Single nucleotide polymorphism (SNP) array analyses were performed with pairs of tumor DNA and blood DNA samples; the Genome-Wide Human SNP Arrays 6.0 (Affymetrix) were used according to the manufacturer's instructions for these analyses. The Genome Imbalance Map algorithm was used to calculate allelic and total genome copy numbers. 19 Multiplex Ligation-Dependent Probe Amplification SALSA P016-C2 VHL probe kits (MRC-Holland) were used for multiplex ligation-dependent probe amplification (MLPA) analyses according to the manufacturer's instructions. The P016-C2 kit contains 9 probes for VHL (4 in exon 1, 3 in exon 2, and 2 in exon 3), 6 probes for genes located on chr. 3p close to VHL, 2 probes for loci on chr. 3p that are telomeric or centromeric relative to VHL, and 12 reference probes for sequences on other chromosomes. Data were generated using GeneMapper Software v4.0 (Applied Biosystems). We determined VHL gene dosage with an Excel template offered by the manufacturer (MRC-Holland). 20 The manufacturer's instructions stated that when allele copy numbers (ACNs) are 1.7 to 2.3 for individual probes, the region is "normal diploid, " and when ACNs are 0.7 to 1.3 for 2 or more adjacent probes, the region has "heterozygous deletion. " Additionally, when ACNs are 1.3 to 1.7 for 2 or more adjacent probes, the region has "suspected heterozygous deletion. "
Methylation-Specific PCR
EZ DNA Methylation Kits (Zymo Research) were used according to the manufacturer's instructions along with genomic DNA samples (250 ng/reaction) for bisulfite modification. For methylation-specific PCR (MSP), the following primers were used as described by Herman et al. 21 Unmethylated specific primers (amplicon length: 165 bp): forward: 5′-GTT GGAGGATTTTTTTGTGTATGT-3′, reverse: 5′-CCCAAACCAA ACACCACAAA-3′. Methylated specific primers (amplicon length: 158 bp): forward: 5′-TGGAGGATTTTTTTGCGTA CGC-3′, reverse: 5′-GAACCGAACGCCGCGAA-3′. PCR was carried out with the following program: 37 cycles of denaturation at 95°C for 30 s, annealing at 59°C for 30 s, and extension at 72°C for 30 s. PCR products were then analyzed by electrophoresis through 1.5% agarose gels. CpG Methylated Jurkat Genomic DNA and 5-Aza dc Jurkat Genomic DNA (New England Biolabs) were used as positive and negative controls, respectively.
Bisulfite Sequencing
For bisulfite sequencing, bisulfite modification was performed as described by Nickerson et al, and the following primers were then used to amplify both methylated and unmethylated allele sites along the VHL promoter. 22, 23 Initial PCR primers (amplicon length: 335 bp): forward: 5′-TTAYGG AGGTYGATTYGGGAG-3′, reverse: 5′-ACRATTACAAAAAAT AACCTA-3′; nested PCR primers (amplicon length: 226 bp); forward: 5′-YGGGTGGTTTGGATYG-3′, reverse: 5′-AATTCAC CRAACRCAACA-3′. Initial PCR was carried out with the touchdown program with an annealing temperature decreasing from 56°C to 50°C. Nested PCRs were then performed with 1 µL of a 1:10 dilution of the first-round reaction and the same PCR program used for first-round amplification. Sequencing reactions were then performed. Based on sequence chromatograms from bisulfite sequencing, the cytosine at several cytosine-phosphate-guanine (CpG) sites remained a cytosine after bisulfite conversion; these findings indicated that the cytosine residue was methylated at each of these sites. Samples with at least 4 out of a total of 11 analyzed CpG sites were considered to be methylated. Determination of methylation status was performed with the online analysis tool QUMA (Quantification tool for Methylation Analysis; http:// quma.cdb.riken.jp/top/quma_main.html, accessed March 16, 2017) . As with MSP, CpG Methylated Jurkat Genomic DNA and 5-Aza dc Jurkat Genomic DNA were used as positive and negative controls, respectively, for bisulfite sequencing.
Statistical Analysis
Student's t-tests (for age) or Fisher's exact tests (for other factors) were used to assess differences between NeuroOncology groups. JMP 11 (SAS Institute) was used for statistical analysis. A probability value <0.05 was considered significant.
Results
Clinical Characteristics of Patients with HB
The clinical characteristics of the patients are shown in Table 1 . Consistent with previous findings, 24 the median age of patients with VHL-related HB was significantly younger than that of patients with sporadic HB (30.1 vs 47.5 y; P = 0.0004, Student's t-test). The majority of tumors were located in the cerebellum, and others were located in the brainstem or spinal cord.
Sequence Analysis Detected VHL Mutations and Small Frameshift Deletions
Results of the genetic analysis are shown in Tables 2  and 3 . For the 32 HBs, direct sequencing analysis of VHL revealed alterations in 11 HBs from 9 patients. The rate of VHL alterations detected by direct sequencing was significantly higher for VHL-related HBs (7/11, 64%) than for sporadic HBs (4/21, 19%) (P = 0.020, Fisher's exact test). Targeted deep sequencing of VHL was performed for 17 sporadic HB specimens in which VHL mutation was not detected by direct sequencing, along with 2 samples (S13 and S14) that showed VHL mutation by direct sequencing as positive controls. Of these 17 sporadic HBs, VHL alterations were revealed in 9 of them. Two different VHL alterations were found in 3 HBs (S1, S13, and S20). However, whether 2 alterations in the same sample existed in a single tumor cell was not clear; in other words, whether these 2 alterations caused biallelic VHL inactivation was not verified.
The positions of VHL alterations identified in our study are summarized in Fig. 1 . All identified VHL alterations were previously reported in the Catalogue of Somatic Mutations in Cancer (COSMIC, http://cancer.sanger.ac.uk/cosmic, accessed March 16, 2017) . Of the 11 VHL-related HBs, 7 (67%) had VHL sequence alterations: 2 types of missense alterations (c.329A>C or c.194C>T) in 3 samples, a splice site mutation (IVS2-1G>T) in 1, and c.216delC deletions in 3. Two HBs from one patient with VHL disease had the same c.329A>C mutation. Identical single base-pair deletions were found in 3 HBs from 2 patients with VHL disease from the same family, indicating that this small frameshift deletion was a germline mutation. Of the 21 sporadic HBs, 13 (62%) had VHL sequence alterations; 3 types of small deletions (c.402delA, c.444delT, or c.370-371ACdel) in 3 samples, a 10-bp insertion (c.309_310insGGCACGGGCC) 
SNP Array Detected a Difference Between VHLRelated and Sporadic HBs with Regard to Copy Number Abnormalities
All results of the SNP array analysis are shown in Supplementary Figure S1 . Among the 32 HBs, loss of 1 of 2 copies of chr. 3 or 3p was found in 14 (44%) samples (Tables 2 and 3 ). In addition, copy-neutral LOHs that denote LOH without copy number loss on chr. 3 or 3p were identified in 5 other cases (Tables 2 and 3 ). In total, 19 (59%) HBs had LOH of chr. 3 or 3p.The incidences of chr. 3 and 3p LOH were similar between VHL-related and sporadic HBs: in VHL-related HBs, 7 of 11 (64%) samples had LOH on chr. 3 or 3p, and in sporadic HBs, 12 of 21 (57%) samples had LOH on chr. 3 or 3p (Table 4 ). In contrast, incidences of chr. 6 or 10 LOH were significantly higher in sporadic HB than in VHL-related HB (43% vs 0%, P = 0.013, Fisher's exact test) (Tables 2 and 3 ).
MLPA Analysis Detected VHL Intragenic Deletions and Losses of Chromosome 3
Of the 11 VHL-related HBs, we could not find any VHL mutations or small deletions by direct sequencing in 4 specimens. However, MLPA analysis revealed that these 4 had The samples with VHL promoter hypermethylation detected also by MSP, while all promoter hypermethylation were consistently detected by bisulfite sequencing. e Sample S14 had multiple LOHs (1p−, 6−, and 9−) and gains (5+, 7+, 13+, and 20+).
In the "other chr. abnormality" column, "6−" means LOH of chromosome 6, "4+" means gain of chromosome 4.
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intragenic deletions within VHL exon 3 ( Fig. 2A) . These intragenic deletions could not be detected by our SNP array analysis because no corresponding SNP probe was present on the arrays for this region. These 4 HBs were from 2 patients from the same family, and therefore the deletion was a germline alteration. In summary, the sequencing and MLPA analysis detected VHL mutation/deletion more frequently in VHL-related HBs than in sporadic HBs (100% vs 62%; P = 0.029, Fisher's exact test) ( Table 4) .
Based on SNP array data, more than half of all HBs (sporadic or disease related) exhibited chr. 3 LOH (19/32, 59%). However, MLPA analysis could detect the chr. 3 loss in only 5 HBs (5/32, 16%, Tables 2 and 3 ). Furthermore, MLPA data regarding chr. 3 losses were ambiguous; specifically, the average measured copy number for probes on chr. 3 involving VHL was approximately 1.5 based on MLPA, but did not approach 1.0, which is the expected value for chromosome segments reduced to 1 copy from 2 copies due to chromosomal loss. A representative MLPA result indicating chr. 3 loss is shown in Fig. 2B . Overall, the MLPA analysis was not sufficient to detect the various patterns of LOH in chr. 3 (Tables 2 and 3 ). Only 26% of samples with chr. 3 LOH detected with SNP arrays were determined to have LOH with MLPA analysis.
VHL Promoter Hypermethylation Was Detected Only in Sporadic HBs
In VHL-related HBs, no case with VHL promoter methylation was detected (Table 2 ). In contrast, VHL promoter hypermethylation was detected by MSP in 2 of the 21 sporadic HBs (6.3%) (Fig. 3A) ; while on bisulfite sequencing, 7 (33%) sporadic HBs were demonstrated to have VHL promoter hypermethylation, including the 2 cases (samples S9 and S17) also detected by MSP technique (Fig. 3B) (Table 3) . Therefore, the bisulfite sequencing is a more sensitive method to detect promoter methylation. VHL promoter hypermethylation was more frequent in sporadic HBs, although no statistically significant difference between these groups was observed (Table 4) .
Biallelic Inactivation of VHL
Here, we defined biallelic inactivation of VHL (2 VHL hits) as the presence of at least 2 of these 3 alterations (intragenic mutation of VHL, chr. 3 LOH involving VHL, or VHL promoter methylation) (Tables 2 and 3 ). As shown in Table 4 , the rates of biallelic VHL inactivation were similar between VHL-related and sporadic HBs (64% vs 52%, P = 0.71, Fisher's exact test). Of the 21 sporadic HBs, 5 had chr. 3p LOH with neither VHL alterations nor VHL promoter methylation.
Discussion
In this study, the rates of verified biallelic VHL inactivation in VHL-related HBs and sporadic HBs were 64% and 52%, respectively, confirming that VHL inactivation is probably the most important mechanism for tumorigenesis of both VHL-related and sporadic HBs, as previously reported for VHL-related and sporadic ccRCC, although the frequency of biallelic VHL inactivation among HBs was not as high as that among ccRCC. 12, 25 In addition, we observed notable differences between VHL-related and sporadic HB with regard to the patterns of genetic or epigenetic alterations, although there were statistical limitations in comparing these 2 groups due to the potential similarity among VHLrelated HBs, since some of the samples were collected from the same patient or siblings. In VHL-related HBs, all samples had mutations or intragenic deletions of VHL. In contrast, sporadic HBs had VHL mutation/deletion at an apparently lower frequency. On the other hand, VHL promoter hypermethylation was observed only in sporadic HBs, and epigenetic suppression of VHL expression may contribute to VHL inactivation in the sporadic tumors. In addition, the higher frequencies of LOH on chr. 6 and 10 in sporadic HBs suggested that HB-causative genes besides VHL reside on these chromosomes.
By direct sequencing, VHL alterations were detected in only 4 of 21 sporadic HBs, a rate similar to that in the previous studies. 14, 15 Here, we could detect VHL alterations in 9 additional sporadic HBs by targeted deep sequencing. Shankar et al 16 also reported that exome sequence analysis and target sequence analysis could detect additional VHL alterations at a similar rate. One possible reason for such a low mutation detection rate with direct sequencing may be the low tumor cell content of HBs, which typically have dense vascular networks containing numerous vasculature and blood cells. However, mutant allele frequencies of VHL were not necessarily lower in samples in which VHL alteration was detected only by targeted deep sequencing in our analysis. The sensitivity of the SNP array to detect copy number abnormalities in HBs was higher than that of MLPA; this difference may be due to the fact that SNP arrays have more probes than MLPA, and because the computational statistical analysis of more probes on chr. 3 with SNP arrays could detect small copy number differences between tumor samples and normal cells. The actual copy number of each LOH region within a tumor was prone to be obscured by the diploid copy number of contaminating normal cells, and the measured ratios would be higher than 1.0 for these mixed cell populations.
By using SNP array analysis that can measure allele-specific copy numbers, we could identify copy-neutral LOH in HB. Because the copy number is normal (2 copies) at these sites of copy-neutral LOH, neither MLPA nor comparative genomic hybridization analysis, which were the methods used for most previous studies, could be used to identify this type of copy number abnormality. Copy-neutral LOH has been shown to occur frequently in various types of tumors. [26] [27] [28] Recently, Shankar et al reported that copyneutral LOH of chr. 3 was present in 2 of 10 sporadic HBs. 16 Our result is concordant with this finding, and together these findings suggest that copy-neutral LOH, along with LOH with accompanying copy number loss, contributes prominently to the biallelic inactivation of VHL. Although we found additional cases with copy-neutral 3p LOH, the overall frequency of chr. 3p LOH was approximately 60% for both VHL-related and sporadic HBs; this rate is lower than that for ccRCCs, which reportedly have rates of chr. 3p LOH between 80% and 90%. 12, 25 To be noted is that the findings from SNP array analysis of different tumors from the same VHL disease patient were not always identical. For example, samples V4-1, V4-2, and V4-3 were from the same patient, and SNP array results for these samples were (i) copy-neutral LOH of chr. 3p, (ii) copy-neutral LOH of chr. 3, and (iii) copy number loss of chr. 3, respectively. These findings confirmed that the second VHL hits are different between tumors from the same patient with VHL disease.
Notably, VHL promoter methylation was identified only in sporadic HBs (7/21 cases; 33%), suggesting that epigenetic suppression of VHL may be relatively common in sporadic HBs. However, the frequency and functional consequences of these promoter methylation events, especially those detected by bisulfite sequencing, have not been clearly documented. Consistent with our results, findings from Prowse et al indicate VHL promoter hypermethylation in 2 of 5 HBs based on methylation-sensitive restriction enzyme analysis. 29 However, Gläsker et al used the same method as Prowse and colleagues and did not find any VHL promoter hypermethylation in 41 HB samples. 14 Muscarella et al also reported that none of the 18 samples they examined had VHL promoter hypermethylation based on MSP. 15 The reason for such inconsistency in these results is unclear. The inconsistency between our findings from MSP and bisulfite 
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sequencing may have been caused by differences in the locations of the targeted CpG sites; as shown at the top of Fig. 3B , the target CpG sites of bisulfite sequencing were located on the 3′ side of the minimal promoter. Although the target CpG sites of MSP primers included the established minimal promoter, 30 whether the CpG sites recognized by each type of analysis technology are really related to suppression of the VHL promoter has not been well studied. Besides promoter methylation, VHL expression can be downregulated by other mechanisms; for example, microRNA may bind to VHL and decrease its expression, as reported in a leukemia cell line. 31 Another possible explanation for less frequent mutation or deletion of VHL alterations in sporadic HBs is the existence of causative gene alterations other than VHL in these sporadic tumors. Several recent studies with wholegenome and whole-exome sequencing analysis have identified several novel candidate genes that may be causative for ccRCCs. These candidates include polybromo 1 (PBRM1), BRCA-1 associated protein 1 (BAP1), and SET domain containing 2 (SETD2), [32] [33] [34] which are all located on chr. 3p, indicating that several novel putative HB-causative genes are located on chr. 3p. However, few reports have yet to comprehensively analyze genomic alterations of HB. [35] [36] [37] [38] SNP array data also demonstrated that 43% of sporadic HBs had LOH on chr. 6 or 10. Four of the 21 sporadic HBs in this study (Table 3) had LOH on chr. 10 or 10q; and a gene encoding a well-known tumor suppressor, phosphatase and tensin homolog (PTEN), resides on chr. 10q. Frew et al report that combined conditional inactivation of VHL and PTEN in the mouse kidney facilitates formations of kidney cysts, which are thought to be precancerous lesions. 39 Therefore, PTEN may also play some role in HB tumorigenesis. Notably, of the 9 sporadic HBs that lacked chr. 3 LOH, 6 (67%) had LOH on chr. 6, chr. 10, or both. These results were in accordance with a previous study on 16 sporadic HBs and 7 VHL-related HBs that were screened for copy number abnormalities via comparative genomic hybridization. 36 This study showed that 10 sporadic HBs (63%) had chr. 3 LOH, 7 (44%) had chr. 6 LOH, 3 (19%) had chr. 10 LOH, and none of the samples with LOH on chr. 6 or 10 were VHL-related HBs. These previous results together with our findings may indicate that chr. 6 or chr. 10 LOH is characteristic of sporadic HBs and that tumorigenesis of sporadic HBs may be through an alternative pathway involving tumor suppressor genes other than VHL that reside on these chromosomes.
In conclusion, the results of the present study indicated that alternative pathways may exist for tumorigenesis of sporadic HB. Whether such difference in the tumorigenic mechanism among hemangioblastomas would require a different approach in the management of the affected patients is an interesting question that should be answered in the future studies.
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